title: Use of intrathecal prophylaxis in allogeneic haematopoietic stem cell transplantation for malignant blood diseases: a survey of the European Group for Blood and Marrow Transplantation (EBMT).
abstract: A survey was carried out among EBMT centres to describe the current practice concerning intrathecal (i.t.) prophylaxis in allogeneic stem cell transplantation for malignant diseases in patients with no central nervous system (CNS) manifestations of the disease at any time. A total of 90 centres reported their practice: 42 centres (47%) never used pre-transplant i.t. prophylaxis as part of the conditioning, whereas 48 centres (53%) gave i.t. prophylaxis to selected groups. The main indications were acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), and lymphoma (53, 33, and 23% of all centres, respectively). Prophylaxis was usually given to all patients with ALL, but often restricted to high-risk patients in AML and lymphoma. Of the 90 centres, 29 (32%) gave prophylactic i.t. treatment after the transplantation, mainly for the same indications as pre-transplant. This survey illustrates the heterogeneity in the current practice of i.t. prophylaxis in allogeneic transplantation for malignant blood disorders in Europe. The documentation in the literature to support the use of i.t. prophylaxis as part of transplantation for malignant diseases in patients without preceding CNS involvement is sparse. Based on the rarity of isolated CNS relapse after allogeneic stem cell transplantation, EBMT does not recommend routine i.t. prophylaxis to patients without prior CNS involvement.
authors.affiliation: Department of Medicine, Helsinki University Central Hospital, POB 340, FIN-00029 HUS, Helsinki, Finland. tapani.ruutu@hus.fi
authors.forename: T
authors.initials: T
authors.lastname: Ruutu
authors.forename: P
authors.initials: P
authors.lastname: Corradini
authors.forename: A
authors.initials: A
authors.lastname: Gratwohl
authors.forename: E
authors.initials: E
authors.lastname: Holler
authors.forename: J
authors.initials: J
authors.lastname: Apperley
authors.forename: G
authors.initials: G
authors.lastname: Dini
authors.forename: V
authors.initials: V
authors.lastname: Rocha
authors.forename: N
authors.initials: N
authors.lastname: Schmitz
authors.forename: G
authors.initials: G
authors.lastname: Socié
authors.forename: D
authors.initials: D
authors.lastname: Niederwieser
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D016543:Central Nervous System Neoplasms / Q000517:prevention & control*; D003625:Data Collection; D019337:Hematologic Neoplasms / Q000473:pathology / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007278:Injections, Spinal; D007938:Leukemia / Q000473:pathology / Q000628:therapy; D008223:Lymphoma / Q000473:pathology / Q000628:therapy; D011292:Premedication / Q000379:methods* / Q000706:statistics & numerical data; D055502:Secondary Prevention; D014184:Transplantation, Homologous
chemical_list: D000970:Antineoplastic Agents